Changchun High-Tech Industries announced that its subsidiary Jin Sai Pharmaceutical has received the "Drug Clinical Trial Approval Notice" approved and issued by the National Medical Products Administration, and the clinical trial application for GenSci122 tablets has been approved. GenSci122 tablets are a Category 1 new Chemical Drug, a selective small molecule KIF18A inhibitor with a new structure, indicated for advanced solid tumors. If the clinical trial application progresses smoothly, it will help the company expand its Business structure, optimize its product structure, enrich and improve the product line layout in strategic areas, and enhance the company's core competitiveness.
- Latest
- Detail
长春高新：子公司GenSci122片临床试验申请获批准
Changchun High-Tech Industries: Subsidiary GenSci's clinical trial application for GenSci122 tablets has been approved.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Risk Disclaimer
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Got it
Risk Disclaimer
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Got it
Write a comment
0 0 0
LikeLoveLaughing CryRespectEmmSadAngry
Tap to Select a Mood
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
Use the share button in your browser
to share the page with your friends
Tap here to share
No comments yet. Write one.
Related Stocks Related Stocks
Symbol Mini Chart Latest Price
Unlock the Full List
Statement
This page is machine-translated. Futubull tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation.